Background. The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking.
The purine analogue abacavir (ABC), a nucleoside reverse-transcriptase inhibitor (NRTI) widely used in the treatment of human immunodeficiency virus (HIV) infection, was observed in 2005 to be associated with a higher risk of myocardial infarction [1] . However, it was only after publication of work by the D:A:D study group in 2008, which correlated current or recent exposure (ie, ≤6 months) to the drug with a 2-fold increment in the incidence of myocardial infarction, that this risk was widely recognized and extended to didanosine (ddI), another purine analogue [2] . A substantial number of subsequent studies confirmed this relationship, but others did not, and the divergent results sparked one of the longest lasting controversies in the area of HIV therapeutics, which is ongoing [1] . Nevertheless, despite the lack of a consensus, major clinical guidelines recommend caution when prescribing ABC to patients at risk of cardiovascular disease [3] .
In addition to discrepancies among the available clinical data [1] , the aforementioned debate has been fueled by the absence of an accepted mechanism of action to justify the cardiovascular toxicity of ABC. The initial D:A:D study pointed to vascular inflammatory mechanisms, as the risk was shown to decrease once the drug was withdrawn and was not related to traditional predisposing factors [2] . Since then, this hypothesis regarding inflammation has been endorsed by clinical and experimental evidence of impaired endothelial function and increased circulation of endothelial cells [1] . Our group has published further evidence of a vascular inflammatory response to ABC; we showed that the drug produced leukocyte-endothelial cell interactions, both in vitro and in vivo, and promoted the adherence of platelets to endothelial cells [4] [5] [6] [7] . In both instances, there were clear signs of interference with purinergic signaling, specifically ATP-P2X 7 receptors [7, 8] . The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs [9] , while the generation of thrombi involves the recruitment of leukocytes and platelets by the endothelium [10] , making the profile of experimental actions demonstrated by ABC compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking, until now.
The present study was designed to address this gap by appraising the effects of ABC in a well-validated animal model of arterial thrombosis. The role of the aforementioned ATP-P2X 7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other NRTIs were evaluated and compared to those of ABC.
METHODS

Intravital Assessment of Arterial Thrombosis
Wild-type (WT) C57BL/6 or homozygous knockout (P2rx7 KO; B6.129P2-P2rx7 tm1Gab /J) male mice (age, 9 weeks; weight, 22-30 g) were anesthetized intraperitoneally with xylazine hydrochloride 10 mg/kg and ketamine hydrochloride 100 mg/ kg (intraperitoneally). The cremaster muscle was exteriorized onto an optical clear viewing pedestal for tissue transillumination, continuously superfused with bicarbonate-buffered saline (pH 7.4, 37ºC, 2 mL/minute), and visualized with an orthostatic microscope (Nikon Optiphot 2, SMZ1; Nikon, the Netherlands) connected to a video camera (Nikon DS-Fi3; Nikon, Japan).
Images (original magnification ×1300) of single unbranched cremasteric arterioles (diameter, 20-35 μm) were captured and analyzed digitally, using the NIS Elements AR program [6, 8] . The resting blood vessel was recorded for 8 minutes, and the induction of thrombosis was evaluated thereafter by means of the ferric chloride model [11] . Different solutions of ferric chloride (80 µL of a 25-75 mM solution) were superfused over the artery, and the 25 mM solution was selected because it did not modify blood flow (Supplementary Figure 1) . As is standard with this technique, images were video recorded until blood flow ceased or, if no vessel occlusion occurred, for a maximum of 8 minutes. Before and 60, 120, 360, 420, and 480 seconds after challenge with ferric chloride, the centerline red blood cell velocity was quantified with an Optical Doppler Velocimeter (Microcirculation Research Institute, Texas A&M College of Medicine, College Station, TX), and the wall shear rate was calculated [6] . These experiments were performed by 2 investigators: one injected the drugs while the other performed the procedure and analyzed the results. The investigator injecting the drug was not masked to treatments, but the one measuring the time to blood-flow cessation was unaware of the treatments administered.
Experimental Protocol
Four hours before intravital assessment, animals were injected intrascrotally with 100 μL of saline or varying concentrations of ABC (range, 2.5-7.5 μg/mL), tenofovir (TDF; range, 0.3-7.5 μg/ mL), ddI (range, 1.2-7.5 μg/mL), emtricitabine (FTC; range, 2.5-7.5 μg/mL), or lamivudine (3TC; range, 2.5-7.5 μg/mL). Intrascrotal administration allows the cremaster tissue to be bathed with the stimulus solution and is standard when evaluating this vascular bed by intravital microscopy [12] . Dosages were selected to mimic local plasma concentrations in patients [7, 8] . In another set of experiments, ABC was administered orally with doses (range, 100-200 mg/kg administered 4 hours before intravital assessment) identified to reproduce in mice the plasma concentrations obtained in humans after receiving a clinical dose (600 mg) [13] . However, to corroborate these dose/plasma correlations, a sample of aortic blood was extracted at the end of each experiment, and plasma levels of ABC were analyzed by ultra-high-pressure liquid chromatography coupled to 6495 triple-quadrupole mass spectrometry [7] . In further experiments, the COX-2 inhibitors diclofenac (0.5-1 mg/ kg, administered intraperitoneally 2 hours before intravital assessment) and rofecoxib (range, 0.01-0.1 mg/kg administered intraperitoneally 2 hours before intravital assessment) were used as positive controls. Some WT mice were pretreated (intraperitoneally) before administration of ABC (5 μg/mL) with receptor antagonists specific for ATP-P2X 7 (A804598; 1 µg/kg administered 30 minutes before ABC treatment) or ATP-P2X 2/3 (A317491; 0.1 µg/kg administered 30 minutes before ABC treatment) at doses that have previously been shown to block leukocyte and platelet parameters [7, 8] .
Materials ABC, TDF, ddI, FTC, and 3TC were obtained from Sequoia Research Products (United Kingdom), ketamine (Imalgene) was obtained from Merial Laboratorios (Spain), rofecoxib, diclofenac sodium salt, xylazine hydrochloride, ferric chloride, A-804598, and A-317491 sodium salt hydrate were from SigmaAldrich (Spain). Wild-type (WT) C57BL/6 mice were from Charles River Laboratories (France), and knockout (P2rx7 KO; B6.129P2-P2rx7 tm1Gab /J) mice were from Jackson Laboratories (United States).
Ethics and Statistics
All animal procedures complied with Spanish law and were approved by the designated ethics committee. Data involving sample sizes of ≥5 are presented as mean values ± standard errors of the mean (SEMs). Results were analyzed with Prism 7.0 software. One-way analysis of variance (ANOVA) was used to analyze the parameter of occlusion time, while shear rate values, which are affected by drug treatment and time, were examined by 2-way ANOVA, with both ANOVAs followed by a Newman-Keuls correction. A P value of <.05 was considered statistically significant.
RESULTS
Pretreatment with ABC intrascrotally (at doses of 2.5, 5, and 7.5 μg/mL) or orally (dose range, 100-200 mg/kg) neither altered blood flow (measured as the vascular wall shear rate) nor resulted in the formation of thrombi (measured as the time to occlusion; data not shown). Likewise, in the absence of any pretreatment, superfusion with 25 or 50 mM of ferric chloride did not affect the aforementioned parameters. However, when the concentration of ferric chloride in the superfusion was augmented to 75 mM, there was a rapid formation of thrombi and a subsequent reduction in wall shear rate characteristic of a cessation of blood flow (Supplementary Figure 1) .
Likewise, the arterioles became occluded when the 25 mM concentration of ferric chloride was perfused over the cremaster of animals intrascrotally pretreated with ABC. This occlusion developed more rapidly as the dose of ABC increased ( Figure 1A and 1B) and was accompanied by a parallel dose-dependent reduction in the arterial wall shear rate ( Figure 1D ). The oral administration of ABC (mean plasma concentration [±SEM], 5.3 ± 0.8 and 16.2 ± 1.9 µg/mL following 100 and 200 mg/kg, respectively) reproduced the effects of locally administered ABC ( Figure 1B) . Superfusion with 25 mM of ferric chloride had no effects in mice pretreated intrascrotally with one of the other NRTIs analyzed (TDF, ddI, FTC, or 3TC), even at concentrations (7.5 µg/mL) substantially higher than those considered clinically appropriate ( Figure 1C ). In contrast, in animals pretreated with a clinical concentration of diclofenac or rofecoxib-2 well-known vascular injurious agents-25 mM of ferric chloride led to the formation of arterial thrombi in a similar way to that produced by the 2 highest doses of ABC evaluated (Figure 2A) .
Selective blockade of P2X 7 receptors but not of other P2X-receptors reverted the prothrombotic effects of ABC ( Figure 2B) . Likewise, the effect of ABC was absent in P2rx7-KO mice, while the prothrombotic actions of both diclofenac and rofecoxib continued to be manifested (Figure 2A) .
DISCUSSION
The present results demonstrate that clinically relevant concentrations of ABC following local or oral administration promote the formation of arterial thrombi in vivo. This effect is dose dependent and specific, as it was not reproduced by any of the other NRTIs analyzed (ie, ddI, 3TC, FTC, and TDF) and involved the activation of ATP-P2X 7 purinergic receptors. Our data are compatible with previous findings-both in vitro (with human cells) and in vivo (with intravital microscopy of mesenteric rat and cremasteric murine veins)-that outline ABC as a vascular inflammatory agent capable of triggering processes that precede the formation of thrombi, in particular the interaction of endothelial cells with either leukocytes or platelets [4] [5] [6] [7] [8] .
Superfusion with ferric chloride is a model of vascular injury widely used to evaluate thrombosis [11] . It has proven to be an effective tool for shedding light on the role of the different pathological pathways implicated in thrombogenesis and for analyzing the prothrombotic or antithrombotic effects of drugs. It involves the induction of a variable degree of endothelial toxicity that leads directly to thrombosis if the concentrations of ferric chloride are high enough. Alternatively, at low concentrations, it predisposes arterioles to the thrombogenic effects of other agents with potential vascular deleterious effects that are administered jointly. This was the case in our experimental conditions, in which the arterioles of control animals did not become occluded following superfusion with 25 mM of ferric chloride, while there was a rapid formation of thrombi when mice had been pretreated with concentrations of ABC within the ranges observed in patients [7, 8] . It is significant that said actions matched the effects induced by clinical concentrations of rofecoxib or diclofenac, 2 drugs whose use clearly correlates with an increased risk of myocardial infarction and that act through a mechanism unrelated to that suggested for explaining the vascular actions of ABC (ie, inhibition of endothelial prostacyclin production following Cox-2 inhibition) [14, 15] .
The chemical structure of ABC is very similar to that of endogenous purines (ie, ATP, ADP, and AMP), molecules capable of triggering proinflammatory and prothrombotic cardiovascular programs by interacting with P2-nucleotide receptors located on a variety of vascular structures, including endothelial cells, leukocytes, and platelets [9] . The fact that the prothrombotic effects of ABC were reverted following selective blockade of P2X 7 -receptors and were absent in P2rx7 KO mice-animals in which the thrombotic actions of rofecoxib were manifestedpoints to the specific involvement of said receptors in the actions of ABC. This association is in keeping with the well-known connection between this purinergic receptor and vascular inflammatory responses [9] and, more specifically, with previous in vivo and in vitro reports implicating ATP-P2X 7 receptors in the effect of ABC on the interplay between the endothelium and leukocytes and platelets [7, 8] . Notwithstanding the close structural similarity between ABC and ddI and the facts that the 2 share some proinflammatory vascular actions and have been correlated with myocardial infarction [2] , ddI did not exhibit any prothrombotic effect in our experimental setting. Although we do not have a clear explanation for this, it is in accordance with some of our previous research in which ddI did not fully reproduce the effects of ABC on platelet-endothelial interplay [7] , and it may be a consequence of the fact that ABC is a guanosine analogue whereas ddI is derived from adenosine.
In summary, our data suggest that ABC generates conditions that favor the development of arterial thrombosis and that this action involves interference with purinergic signaling. Indeed, the extent of such a risk seems to be similar to that attributed to other well-known vascular-damaging agents, such as diclofenac or rofecoxib. There is call for caution when extrapolating experimental data to a clinical setting, since they may not fully reflect events that occur in humans. However, our data support a profile of actions of ABC compatible with the induction of vascular inflammation, and they point to a plausible pharmacological explanation for the clinical association of ABC with cardiovascular diseases.
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